Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases

BACKGROUND: Fibrosing, non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung diseases (fILDs) are a heterogeneous group of diseases characterized by a different amount of inflammation and fibrosis. Therapy is currently based on corticosteroids and/or immunomodulators. However, response to th...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Pulm Med
Главные авторы: Torrisi, Sebastiano Emanuele, Kahn, Nicolas, Wälscher, Julia, Sarmand, Nilab, Polke, Markus, Lars, Kehler, Eichinger, Monika, Heussel, Claus Peter, Palmucci, Stefano, Sambataro, Francesca Maria, Sambataro, Gianluca, Sambataro, Domenico, Vancheri, Carlo, Kreuter, Michael
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2019
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6852748/
https://ncbi.nlm.nih.gov/pubmed/31718637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-019-0937-0
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы